Lindsay Yoder, PA
Physician Assistant · Indianapolis, INNPI 1184918161
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Madrigal Pharmaceuticals at 45.3% of the total. 2025 is the largest year on record at $19,415, more than ten times the $18 reported in 2021. Among physician assistant clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 52 payments — averaging $402.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$9K
- Gilead$7K
- Ipsen Biopharmaceuticals, Inc$3K
- Novo Nordisk$1K
- AbbVie$132
- Otsuka Pharmaceutical Development & Commercialization, Inc.$99
- plus $87 from 3 others
Across 18 payments — averaging $111.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
What the payments were for
- Consulting fees$6,08829%
- Speaking & faculty fees$9,53546%
- Travel & lodging$2,99514%
- Food & beverage$2,26611%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 16 | $9,465 |
| Gilead | 22 | $7,321 |
| Ipsen Biopharmaceuticals, Inc | 4 | $2,749 |
| Novo Nordisk | 4 | $1,063 |
| AbbVie | 1 | $132 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $99 |
| Merck | 2 | $45 |
| Abiomed | 1 | $23 |
| Medtronic | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$9,193
- Livdelzi$6,321
- IQIRVO$1,989
- Mavyret$132
- RESMETIROM$123
How this compares
$20,916 in reported general payments places this provider in the 95th percentile of 1,955 physician assistant providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 169 | $576,548 |
| RezdiffraResmetirom | 40 | $161,501 |
| Ursodiol | 146 | $25,612 |
| Lactulose | 67 | $3,645 |
| Mycophenolate Mofetil | 39 | $3,497 |
| Azathioprine | 54 | $2,343 |
| Hydroxyzine Hcl | 12 | $1,112 |
| Spironolactone | 91 | $930 |
| Carvedilol | 84 | $610 |
| Amiloride Hcl | 28 | $595 |
| Tenofovir Disoproxil Fumarate | 17 | $531 |
| Furosemide | 122 | $498 |
| Omeprazole | 21 | $258 |
| Tacrolimus | 12 | $255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Madrigal PharmaceuticalsRezdiffra | $9,465 | $161,50140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,955 physician assistant providers in Indiana.
Other physician assistant in Indianapolis
- Andrew NordIndianapolis$47K
- Qun Ming ZhangIndianapolis$28K
- Mackenzie LawsonIndianapolis$15K
- Christina RaceIndianapolis$13K
- Zara BogenschutzIndianapolis$12K
- Ashley WorthingtonIndianapolis$11K
- Madison MaloofIndianapolis$10K
- Michaela WehrIndianapolis$10K
- Ryan RosebroughIndianapolis$8K
- Anne SmrekIndianapolis$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.